1054 related articles for article (PubMed ID: 23457381)
1. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
3. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis.
Harrison BJ; Hutchinson CE; Adams J; Bruce IN; Herrick AL
Ann Rheum Dis; 2002 Nov; 61(11):1007-11. PubMed ID: 12379525
[TBL] [Abstract][Full Text] [Related]
4. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
6. Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry.
Szentpetery A; Heffernan E; Haroon M; Kilbane M; Gallagher P; McKenna MJ; FitzGerald O
Rheumatology (Oxford); 2016 May; 55(5):891-6. PubMed ID: 26850991
[TBL] [Abstract][Full Text] [Related]
7. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
8. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
[TBL] [Abstract][Full Text] [Related]
9. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
10. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
[TBL] [Abstract][Full Text] [Related]
11. Relationship of bone turnover to bone density and fractures.
Melton LJ; Khosla S; Atkinson EJ; O'Fallon WM; Riggs BL
J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
[TBL] [Abstract][Full Text] [Related]
12. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
Seriolo B; Paolino S; Sulli A; Cutolo M
Reumatismo; 2006; 58(3):199-205. PubMed ID: 17013436
[TBL] [Abstract][Full Text] [Related]
13. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis.
Orsolini G; Adami G; Adami S; Viapiana O; Idolazzi L; Gatti D; Rossini M
Calcif Tissue Int; 2016 Jun; 98(6):580-5. PubMed ID: 26887973
[TBL] [Abstract][Full Text] [Related]
16. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
[TBL] [Abstract][Full Text] [Related]
18. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
19. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
20. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]